Format

Send to

Choose Destination
J Am Coll Cardiol. 2014 Dec 16;64(23):2525-40. doi: 10.1016/j.jacc.2014.09.042.

Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease.

Author information

1
Mount Sinai Heart, Cardiometabolic Disorders, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: robert.rosenson@mssm.edu.
2
Division of Cardiology, Pritzker School of Medicine, University of Chicago, Chicago, Illinois.
3
Mount Sinai Heart, Mount Sinai Hospital, New York, New York.
4
Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
5
ECOGENE-21 and Lipid Clinic, Department of Medicine, Université de Montreal, Chicoutimi, Quebec, Canada.

Abstract

Triglycerides represent 1 component of a heterogeneous pool of triglyceride-rich lipoproteins (TGRLs). The reliance on triglycerides or TGRLs as cardiovascular disease (CVD) risk biomarkers prompted investigations into therapies that lower plasma triglycerides as a means to reduce CVD events. Genetic studies identified TGRL components and pathways involved in their synthesis and metabolism. We advocate that only a subset of genetic mechanisms regulating TGRLs contribute to the risk of CVD events. This "omic" approach recently resulted in new targets for reducing CVD events.

KEYWORDS:

atherosclerosis; cardiovascular disease; genetics; triglyceride; triglyceride-rich lipoproteins

PMID:
25500239
DOI:
10.1016/j.jacc.2014.09.042
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center